Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 327 | 2020 |
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade CRG Stroud, A Hegde, C Cherry, AR Naqash, N Sharma, S Addepalli, ... Journal of Oncology Pharmacy Practice 25 (3), 551-557, 2019 | 283 | 2019 |
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis H Abu-Sbeih, FS Ali, AR Naqash, DH Owen, S Patel, GA Otterson, ... Journal of clinical oncology 37 (30), 2738-2745, 2019 | 174 | 2019 |
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease H Abu-Sbeih, DM Faleck, B Ricciuti, RB Mendelsohn, AR Naqash, ... Journal of Clinical Oncology 38 (6), 576-583, 2020 | 165 | 2020 |
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 163 | 2022 |
Characterization of KRAS mutation subtypes in non–small cell lung cancer J Judd, N Abdel Karim, H Khan, AR Naqash, Y Baca, J Xiu, ... Molecular cancer therapeutics 20 (12), 2577-2584, 2021 | 103 | 2021 |
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 100 | 2021 |
Emerging role of immune checkpoint blockade in pancreatic cancer S Macherla, S Laks, AR Naqash, A Bulumulle, E Zervos, M Muzaffar International journal of molecular sciences 19 (11), 3505, 2018 | 98 | 2018 |
Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 88 | 2021 |
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy P Srivastava, BE Paluch, J Matsuzaki, SR James, G Collamat-Lai, ... Oncotarget 7 (11), 12840, 2016 | 81 | 2016 |
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort AR Naqash, B Ricciuti, DH Owen, V Florou, Y Toi, C Cherry, M Hafiz, ... Cancer Immunology, Immunotherapy 69, 1177-1187, 2020 | 79 | 2020 |
Epigenetics: A primer for clinicians BE Paluch, AR Naqash, Z Brumberger, MJ Nemeth, EA Griffiths Blood reviews 30 (4), 285-295, 2016 | 67 | 2016 |
Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment J Ansari, AR Naqash, R Munker, H El‐Osta, S Master, JD Cotelingam, ... European journal of haematology 97 (1), 9-16, 2016 | 66 | 2016 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 63 | 2022 |
Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 58 | 2020 |
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 57 | 2020 |
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 54 | 2021 |
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 52 | 2021 |
Association between immune-related adverse event timing and treatment outcomes D Hsiehchen, AR Naqash, M Espinoza, MS Von Itzstein, A Cortellini, ... Oncoimmunology 11 (1), 2017162, 2022 | 47 | 2022 |
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021 | 47 | 2021 |